Esperovax and Life Magnetics to Deliver New Oral Therapeutic to Colorectal Patients

biospace

Esperovax, a leading developer of oral mRNA biologics, and Life Magnetics, Inc., creators of RNA stabilization technology, today announced the signing of an agreement to co-develop an innovative new oral RNA therapeutic delivery system for colorectal cancer patients that can be stored at room temperature.

Oral and room temperature delivery of RNA therapeutics is a holy grail for the pharmaceutical industry. RNA therapeutics are safer, easier to design, and have far more targets than small molecule drugs. To date, the major limitation of RNA therapeutics is product shelf life. For example, the lifetime of mRNA is only around 7 hours at room temperature.

Read Full Article ->

Recent News

Esperovax Awarded Subcontract for Development of Thermostable Oral Vaccine Platform

December 12, 2024

Esperovax Awarded $1M for Development of an Oral COVID-19 RNA Vaccine under the HHS Project NextGen Initiative 

August 23, 2023

Esperovax Appoints Dr. Robin Robinson as President and CEO

April 29, 2023

Esperovax, Ginkgo Bioworks Join Hands To Develop Circular RNA-based Therapeutics

January 10, 2023

Esperovax Signs Exclusive Licensing Agreement with the University of Michigan for a Novel Manufacturing Technology for the Production of Vaccines and Therapeutics

November 30, 2022

Esperovax Selected as a
BLUE KNIGHT™ Company

February 14, 2022

Global Thermostable Vaccines and Thermostable Biologics Market to 2035 – by Type of Molecule, Target Indications, Type of Therapy, Key Players and Region – ResearchAndMarkets.com

January 1, 2022

Esperovax Co-Founders Published in Separation and Purification Technology Journal

May 15, 2021

Michigan Rise Invests in Esperovax

April 29, 2021

The Sleeping Giants of Vaccine Production Awaken

February 3, 2021